Figure 6. Involvement of the Wnt/β-catenin pathway in the protective effect of GYY4137 against Dex-induced osteoblast activities. (A) mRNA expression of Wnt-signaling target genes was measured in primary osteoblast pretreated with Dex or/and GYY4137. n=3, *p<0.05, **p<0.01. (B–C) Immunofluorescence staining of the osteoblast after a 2-day incubation with Dex or/and GYY4137. (D–E) Effect of the wnt/β-catenin inhibitor on the protein expression of wnt3a, wnt6, β-catenin at 48hr with GYY4137 pretreatment in Dex-induced osteoblast activities. n=3, *p<0.05, **p<0.01.